Skip to main content
2025 STS Annual Meeting Main banner
Back

General Thoracic

Multimodal Treatment of Pleural Mesothelioma after the MARS-2 trial: Will We Change Our Ways?

Neoadjuvant Immunotherapy in the Treatment of Pleural Mesothelioma

Saturday, January 25, 2025
11:10am – 11:18am PT
Location: 408A

    Invited Speaker(s)

  • Bryan M. Burt, MD

    Professor of Surgery, Division Chief of Thoracic Surgery
    University of California, Los Angeles
    Woodland Hills, California, United States

    Disclosure(s): Bayou Surgical, Inc: Owner/Co-Owner Founder/Co-Founder (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), This is a startup company that I founded which is commercializing a device for minimally invasive surgery (Ongoing)

Disclosure(s):
Bryan M. Burt, MD: Bayou Surgical, Inc: Owner/Co-Owner Founder/Co-Founder (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), This is a startup company that I founded which is commercializing a device for minimally invasive surgery (Ongoing)